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Abstract
Epidemiological and clinical data indicate that genital ulcer disease (GUD) pathogens are associated with an
increased risk of human immunodeficiency virus type 1 (HIV-1) acquisition and/or transmission. Among them,
genital herpes simplex virus type 2 (HSV-2) seems to play a relevant role. Indeed, the ability of HSV-2 to induce
massive infiltration at the genital level of cells which are potential targets for HIV-1 infection may represent one of
the mechanisms involved in this process. Here we show that infection of human primary macrophages (MDMs) by
HSV-2 results in an increase of CCR5 expression levels on cell surface and allows higher efficiency of MDMs to
support entry of R5 HIV-1 strains. This finding could strengthen, at the molecular level, the evidence linking HSV-2
infection to an increased susceptibility to HIV-1 acquisition.
Findings
Herpes simplex virus (HSV), and especially HSV type 2,
represents one of the most widely spread pathogen
causing genital ulcer disease (GUD). Different studies
have associated GUD aetiological agents in general, and
HSV-2 in particular, with a higher risk to acquire and/
or transmit HIV-1 infection [1-3]. A number of biologi-
cal and molecular factors may explain this evidence.
Both the physical disruption of the epithelial/mucosal
barrier and the cellular inflammatory response charac-
terizing GUD could facilitate HIV-1 acquisition, by pro-
viding the virus with access to a large number of CD4-
positive cells. Moreover, several in vitro studies have
underlined molecular mechanisms by which HSV can
directly influence the HIV life cycle in HSV-HIV coin-
fected cells [2,4]. Finally, randomised controlled trials
have been conducted in coinfected individuals to evalu-
ate the effect of HSV-2 suppressive therapy on HIV-1
genital shedding and plasma HIV-1 RNA, showing, in
most cases, a negative impact on HIV-1 replication
[5-7]. A recent study conducted by Zhu and co-workers
[8] showed a persistence of HIV receptor-positive cells
in genital skin after HSV reactivation. In the genital tract,
macrophages represent one of the main target of HIV-1,
especially during primary infection. In this study we
wanted to analyze the ability of HSV-2 to infect human
macrophages and to influence HIV-1 super-infection.
Firstly, we selected the human monocyte U937 cell
line (ATCC
® Number CRL-1593.2) as experimental set
and we infected them with HSV-2, strain G (kindly pro-
vided by Dr. Peggy Marconi, University of Ferrara,
Italy). Briefly, the virus was grown and titrated by plaque
assay on African green monkey kidney cells (Vero), as
previously described [9]. U937 cells (1 × 10
6)w e r e
infected with HSV-2 at two different multiplicity of
infection (MOI of 1 and 10 plaque forming unit, PFU,
per cell). Cells were left in contact with the virus for
two hours at 37°C and, after three washing with phos-
p h a t eb u f f e r e ds a l i n e( P B S ) , cultured in Roswell Park
Memorial Institute medium (RPMI 1640), with addition
of 10% heat-inactivated foetal bovine serum (complete
medium). HSV-2 replication was followed by titration of
the virus released in the cellular supernatant. In contrast
with fully permissive Vero cells, our data show that
U937 cells do not support a significant HSV-2 replica-
tion and that, at least in the case of the MOI of 1 PFU/
cell, the viral titre declines over time (Figure 1A). It has
been previously reported that monocytes display an
intrinsic resistance to HSV type 1 (HSV-1) infection,
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monocytic pathway into functionally and morphologi-
cally mature non-proliferating cells, that can be achieved
by 12-O-tetradecanoylphorbol-13-acetate (TPA) treat-
ment [10-12].
Thus, in order to analyze whether the low susceptibil-
ity to HSV-2 infection displayed by U937 cells could be
related to their differentiation level, the cells were
induced to differentiate by treatment with TPA (50 ng/
ml). After twelve hours of incubation, U937 cells were
washed twice with PBS and cultured for additional
twenty-four hours in TPA-free medium, in order to
avoid possible effects of residual TPA. The percentage
of cells positive for CD14 surface expression, a marker
of macrophage differentiation [13], was then determined
by Fluorescence-Activated Cell Sorting (FACS). Briefly,
1×1 0
6 cells were harvested and directly incubated for
one hour in cold PBS containing 1:100 (v/v) of an anti-
human CD14 primary antibody (Li StarFISH). A fluores-
cein isothiocyanate (FITC)-conjugated anti-rabbit immu-
noglobulin G antibody (Santa Cruz) was employed as
s e c o n d a r ya n t i b o d ya n dt h ef l u o r e s c e n c ew a se v a l u a t e d
by FACS analysis (FACScalibur, Beckton Dickinson). As
reported in Figure 1B, after TPA treatment the percen-
tage of CD14-positive U937 cells is significantly
increased. Differentiated U937 cells were infected with
HSV-2 (MOI of 1 PFU/cell). Infectious virus yields,
which peaked approximately three days post-infection,
appear to be significantly higher than those obtained
from undifferentiated U937 cells (Figure 1C). Thus, our
data suggest that HSV-2 replication efficiency is depen-
dent on the differentiated phenotype of U937 cells along
the monocytic pathway. Interestingly, while untreated
U937 cells did not display a significant HSV-2 induced
cytopathic effect (CPE), TPA-differentiated U937 cells
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Figure 1 HSV-2 ability to infect human monocyte cell line U937 relies on their differentiation level. A) HSV-2 replication in
undifferentiated U937 cells. The U937 cell line was infected with two different MOI of HSV-2, as reported in the graph legend. Vero cells were
infected as a control. HSV-2 titre in the cellular supernatants was measured by plaque assay, at different times post-infection (p.i.). B) Effect of
TPA treatment of U937 cells on CD14 expression. The effect of TPA treatment on U937 cell differentiation state was analyzed by CD14 FACS
analysis. The percentage of positive cells is reported. C) HSV-2 replication in TPA-treated U937 cells. Undifferentiated or TPA-treated U937 cells
were infected with HSV-2 (MOI of 1 PFU/cell). HSV-2 titre in the cellular supernatant was measured by plaque assay. In all cases, the reported
values represent the mean of four independent experiments. The error bars represent the standard deviation.
Sartori et al. Virology Journal 2011, 8:166
http://www.virologyj.com/content/8/1/166
Page 2 of 6Next, infection of primary monocyte-derived macro-
phages (MDMs) was performed. MDMs were obtained
from at least three pooled buffy coats of HIV-1 serone-
gative healthy blood donors, by Ficoll-Hystopaque gradi-
ent, followed by plastic adherence of PBMCs for sixteen
hours in complete RPMI. Non-adherent cells were
removed, and adherent cells were extensively washed
with PBS and grown in complete RPMI supplemented
with Granulocyte-Macrophage Colony-Stimulating Fac-
tor (GM-CSF, 500 U/ml). The cells were cultured for
one week, before evaluating the preparation purity by
measuring the percentage of CD14-positive cells
through FACS analysis, as described above. The cut-off
employed to accept the purity of MDM preparation was
a CD14-positive percentage higher than 90% [13]. Puri-
fied MDMs (2 × 10
6) were infected with HSV-2 strain G
at two different MOIs, 10 PFU/cell and 1 PFU/cell, fol-
lowing the same experimental procedure described for
the U937 cell line. After viral adsorption, the infected
MDMs were maintained in complete RMPI medium
supplemented with GM-CSF. Our data show that
MDMs support HSV-2 replication. As expected, at the
MOI of 10 PFU/cell the infection appears to be more
efficient, achieving a peak in the viral titre seventy-two
hours post-infection (Figure 2A). No clear viral induced
CPE could be observed at any time post-infection (data
n o ts h o w n ) .N e x t ,w ea n a l y z e dt h ee f f e c to fH S V - 2
infection on HIV-1 receptor and coreceptors expression
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Figure 2 HSV-2 infects human MDMs and alters CD4 and CCR5 expression on the cell surface. A) HSV-2 replication in human MDMs.
Purified human MDMs were infected with two different MOI of HSV-2, as indicated. HSV-2 titre in the cellular supernatants was measured by
plaque assay at different times post infection (p.i.). B) Effect of HSV-2 infection on CD4 and CCR5. Uninfected MDMs (HSV-2 -) and HSV-2 infected
MDMs (HSV-2 +) were analyzed for CD4 and CCR5 cells surface expression by FACS analysis, 72 hours post infection. The percentage of CD4 and
CCR5 positive cells is reported (left panel). The right panel reports the FACS histograms showing the mean fluorescence intensity for both CD4
and CCR5 molecules in uninfected (black line) and HSV-2 infected (red line) MDMs. When values are reported, they represent the mean of four
independent experiments. The error bars represent the standard deviation. Statistically significant differences between HSV-2 infected and un-
infected cells, identified by employing the unpaired t-Student test, are indicated with the star (p < 0.05).
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Page 3 of 6on macrophage cell surface. Indeed, HIV-1 entry into
target cells involves the interaction of the viral envelope
glycoproteins with the host cell receptors, CD4, and one
of two coreceptors CCR5 or CXCR4. The chemokine
receptors CXCR4 and CCR5 represent indeed the core-
ceptors for T-cell-tropic (X4-tropic) and macrophage-
tropic HIV-1 (R5-tropic) strains, respectively. Dual/
mixed-tropic populations are also present in HIV
infected patients and evidence has been collected in
antiretroviral-naive patients suggesting that the majority
of viruses within these dual/mixed-tropic populations
use CCR5 [14]. Moreover, natural history studies of
HIV-1 infection have shown that most patients harbour
R5-tropic virus populations soon after infection
and through the asymptomatic phase [15,16]. Thus,
R5-tropic strains appear to be the most relevant during
HIV-1 acquisition and early phases of infection. Taking
into account all these considerations, we focused our
attention on HIV-1 CD4 receptor and on the CCR5 cor-
eceptor. 2 × 10
6 purified MDMs were infected with
HSV-2 at the MOI of 10 PFU/cells and, seventy-two
hours later, the cells were harvested and analyzed by
FACS for the level of CD4 and CCR5 surface expres-
sion. In particular, either a CD4 (1:200 v/v, BD Phar-
mingen) or a CCR5 (1:50 v/v, BD Pharmingen) specific
primary antibody, along with a FITC-conjugated anti-
rabbit immunoglobulin G secondary antibody (Santa
Cruz), were employed on fresh MDMs. Our data show
that the percentage of both CD4 and CCR5 positive
cells increases after HSV-2 infection (Figure 2B) (p <
0.05). At the same time, also the expression levels of
HIV-1 receptor and coreceptor on the cell surface is
slightly enhanced, as indicated by the shift in the mean
fluorescence intensity displayed by the FACS histograms
(Figure 2C).
In order to analyze whether the HSV-2 effect on
CCR5 expression may have an impact on HIV-1 ability
to enter macrophages, we employed a modified version
of the previously described env-complementation assay,
in which the HIV-1 envelope glycoprotein, expressed in
trans, complements a single round of replication of an
env-deleted provirus expressing the chloramphenicol
acetyltransferase (CAT) gene [17,18]. Since the defective
HIV is capable of only one cycle of replication, this
complementation assay allows us to quantitatively mea-
sure the abilities of the cells to support the entry of
HIV-1 variants containing different envelope glycopro-
teins, by evaluating the level of CAT expression in the
target cells. This assay represents an invaluable tool to
dissect the contribution of viral/cellular determinants
involved in HIV-1 entry [17,18]. Recombinant HIV-1
viruses were produced by cotransfection of human
embryonic kidney cells (293T, ATCC
® Number: CRL-








is a derivative of the pSVC21, containing the HIV-1
HXBc2 molecular clone [19], where the vpu, vpr and nef
sequences were substituted with those derived from the
pNL4-3 (vpu/vpr)[ 2 0 ]a n dp L A I( nef) [21] molecular
clones, in order to introduce functional vpu, vpr and nef
genes. Starting from the pSVCvpr
+vpu
+nef
+,w ei n t r o -
duced by molecular biology techniques a 580 bp dele-
tion (nucleotides 7041-8621) in the env gene and cloned
the chloramphenicol acetyltransferase (CAT), obtained
from the v653 RtatC vector [22], at the BamHI site
(nucleotide 8053) [19]. The CAT gene is under the tran-
scriptional control of the HIV-1 LTR and is expressed
from a subgenomic mRNA generated by the same spli-
cing events used for the natural HIV-1 nef message. Dif-
ferent pSVIIIenv plasmids encoding the HIV-1 Rev
protein along with the envelope glycoproteins derived
from laboratory-adapted T-cell-tropic (HXBc2), macro-
phage-tropic (JRF-L and ADA) and primary dualtropic
(89.6) HIV-1 isolates, which can use CXCR-4 [23],
CCR5 [24] or either one [25] respectively, as a corecep-
tor, were adopted. Since the viral proteins are expressed
in a context similar to that occurring in the authentic
provirus, the levels of gene expression achieved are
expected to resemble those in HIV-1-infected cells.
Briefly, 293T cells were cotransfected by the calcium
phosphate method with 20 μgo ft h ep S V C v p r
+vpu
+nef
+Δenv-CAT plasmid and 5 μg of pSVIIIenv plasmids
expressing the HIV-1 HXBc2, ADA, JRF-L, or 89.6
envelope glycoproteins to produce recombinant virions.
Control viruses lacking envelope glycoproteins were pro-




Twelve hours post-transfection, 293T cells were
washed and cultured in RPMI supplemented with 10%
FBS. Conditioned medium containing recombinant
viruses was harvested and filtered (0.45-μm-pore-size fil-
ter) twenty-four hours later. Recombinant viral particles
were quantified by reverse transcription (RT) assay.
Briefly, virions were precipitated from 1 ml of the fil-
tered supernatants by centrifugation at 13,000 rpm for
sixty minutes at 4°C. The precipitate was resuspended in
10 μl of a buffer containing 50 mM Tris-HCl pH 7.5, 1
mM dithiothreitol (DTT), 20% glycerol, 250 mM KCl
and 0.25% (v/v) Triton X-100, transferred in dry ice and
lysed through three cycles of freezing and thawing. The
sample was added to a reaction mixture containing 50
mM Tris-HCl pH 7.5, 7.5 mM MgCl2,0 . 0 5 %( v / v )T r i -
ton X-100, 5 mM DTT, 100 μg/ml polyA, 10 μg/ml
oligo-dT and 2 μCi of
3H-dTTP (43 Ci/mmole) in a
final volume of 50 μl. The reaction was incubated for
one hour at 37°C and then transferred on Whatman fil-
ters. Filters were immediately washed three times in
SSC 2× (0.3 M NaCl, 0.03 M sodium citrate pH 7.2) for
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Page 4 of 610 minutes each, twice in absolute ethanol for ten sec-
onds each and then dried. The radioactivity was mea-
sured by using a scintillator (Rackbeta 1214 Wallac) and
expressed in counts per million (cpm). In parallel, 1.5 ×
10
6 of purified MDMs were cultured in complete RPMI
containing GM-CSF in six-well plates for one week,
before being infected with HSV-2 at the MOI of 10
PFU/cell, as previously described. Seventy-two hours
later, the cells were transduced with 100,000 H
3 cpm
RT units of the different HIV-1 recombinant particles
previously generated and expressing the CAT reporter
gene. Seventy-two hours post-transduction, the MDMs
were harvested, lysed in 150 μl of 250 mM Tris-HCl pH
7.5 and then assayed for CAT activity, as previously
described [22]. The different forms of acetylated chlor-
amphenicol were separated by thin layer chromatogra-
phy (TLC) and visualized with an autoradiografic
exposure of twelve hours (Kodak Biomax films). The
quantitative evaluation was obtained by cutting the TLC
paper at the level of the corresponding spots, and by
performing a quantification of the spots at the scintilla-
tor. The percentage of conversion in the acetylated
forms was calculated as follows:
% of conversion = (mono- + di-acetylated forms)/
(non acetylated + mono- + di-acetylated forms). Calcu-
lated with the above formula, the percentage of con-
version is linear for values up to 50%. Results are
reported in Figure 3. As expected, the X4-tropic virus
(HXBc2 env) does not infect efficiently MDMs, while
t h ed u a lt r o p i cs t r a i n( 8 9 . 6env) displays the higher
efficiency of infection in all the conditions tested. Our
data demonstrate that, following HSV-2 infection, the
ability of HIV-1 to superinfect target cells is overall
enhanced. The effect is statistically significant (p <
0.05) when R5-tropic recombinant viral particles are
examined, correlating this observation, at least par-
tially, with the HSV-2 related increase in CCR5 expres-
sion levels on MDMs surface. Not surprisingly [25],
the 89.6 dual tropic strain was extremely efficient in
macrophage infection and the observed slight increase
in HIV-1 entry upon HSV-2 infection (Figure 3) was
not statistically significant (p > 0.05).
As mentioned above, interaction between HIV-1 and
other sexually transmitted disease pathogens has been a
subject of extensive investigation [1-9]. In particular,
HSV-2 by affecting genital mucosa integrity and the
function of cells physiologically forming a barrier against
HIV-1 infection, such as Langherans cells [26], alters the
cellular environment at the portal entry and facilitates
HIV-1 acquisition/transmission [27]. Significantly, in
this study we demonstrate that HSV-2 infected macro-
phages, which represent one of the main target for HIV-
1 infection at the genital mucosal site, display an
enhanced expression of HIV-1 CCR5 coreceptor. This
feature renders the cells more susceptible to infection
especially by R5-tropic HIV-1 strains, which play a sig-
nificant role in primary infection [14-16]. Human
macrophages constitutively express HSV receptor
HVEM (herpesvirus entry mediator) [28] and can be
infected by HSV-2 [28, this report]. Taking into account
this evidence and in vivo data demonstrating the enrich-
ment of HIV receptor-positive inflammatory cells in the
HSV-2 positive patient genitalia [8], our results describe
one of the possible molecular mechanisms by which
genital herpes may facilitate HIV-1 acquisition in HSV-
2/HIV-1 coinfected patients.
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Figure 3 Effect of HSV-2 infection on HIV-1 entry into MDMs.
Single round replication HIV-1 recombinant particles pseudotyped
by different envelopes (HIV-env) were employed to transduce
uninfected (HSV-2 -) or infected (HSV-2 +) MDMs, 72 hours post
HSV-2 infection. The entry into cells was analyzed by CAT assay
performed on the cell lysates, normalized for protein content. The
percentage of CAT conversion is reported and represents the mean
of four independent experiments. The error bars represent the
standard deviation. Statistically significant differences between HSV-
2 infected and un-infected cells, identified by employing the
unpaired t-Student test, are indicated with the star (p < 0.05).
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